LOCALIZATION OF I-131-LABELED TUMOR-SPECIFIC MONOCLONAL-ANTIBODY IN THE TUMOR-BEARING BALB-C MOUSE

  • 1 January 1980
    • journal article
    • research article
    • Vol. 21 (6), 570-573
Abstract
One of the most frequent indications for patient imaging is the need to establish the presence or absence of malignant disease. Considerable effort has been invested in attempting to develop tumor-specific radiopharmaceuticals. A 131I-labeled, hybridoma-derived monoclonal antibody was localized in the MH-15 teratocarcinoma-bearing BALB/c mouse. Tumor-to-muscle and tumor-to-blood ratios of 150:1 and 15:1, respectively, were observed at 5 days after administration of 15 .mu.Ci of labeled antibody. The relationship between the optimal imaging time and localization kinetics is discussed.